10-Q: InMed Pharmaceuticals Reports Increased Revenue but Continues to Face Going Concern Challenges in Latest Quarterly Results

InMed Pharmaceuticals saw a significant increase in revenue from its BayMedica segment but continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.

Summary

• InMed Pharmaceuticals reported a net loss of $4.0 million for the six months ended December 31, 2023, compared to a $5.6 million loss for the same period in 2022.
• The company's BayMedica segment saw a substantial increase in sales, reaching $2.1 million for the six months ended December 31, 2023, up from $0.8 million in the same period of 2022.
• Despite the revenue growth, InMed's operating expenses remain high, with research and development costs decreasing but still significant.
• The company has an accumulated deficit of $105.4 million as of December 31, 2023, and expects to continue generating operating losses.
• InMed's cash, cash equivalents, and short-term investments totaled $9.5 million as of December 31, 2023, which is expected to fund operations into the third quarter of 2024.
• The company has raised $4.7 million through a private placement of common shares during the six months ended December 31, 2023.
• InMed has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with positive revenue growth in the BayMedica segment, but this is overshadowed by significant losses, a going concern warning, and a material weakness in internal controls. The need for further capital raises and the risk of delisting from Nasdaq further contribute to a negative sentiment.

Positives

• The BayMedica segment experienced significant revenue growth, indicating a strong market for its rare cannabinoid products.
• The company's net loss decreased compared to the same period last year, suggesting some improvement in financial performance.
• InMed successfully raised additional capital through a private placement, providing funds for ongoing operations.
• The company is actively working to remediate the identified material weakness in internal controls over financial reporting.

Negatives

• InMed continues to incur significant operating losses and negative cash flows.
• The company has a substantial accumulated deficit of $105.4 million.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• The company's future viability is dependent on its ability to raise additional capital.
• The company identified a material weakness in internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain, depending on its ability to raise additional capital.
• The company may not be able to obtain financing on acceptable terms, or at all.
• The terms of any financing may adversely affect the holdings or the rights of the company's existing shareholders.
• The company's operating expenses are expected to increase as it continues to advance its drug candidates and manufacturing technologies.
• The company is subject to various legal proceedings and claims, including a dispute with a licensor.
• The company's common shares are at risk of being delisted from the Nasdaq due to not meeting the minimum bid price requirement.

Future Outlook

The company expects to continue to generate operating losses for the foreseeable future and will need to raise additional capital to finance its operations. The company's future performance is dependent on the success of its product development and commercialization efforts, as well as its ability to secure additional funding.

Management Comments

• The company is dedicated to delivering new therapeutic alternatives to patients and consumers who may benefit from cannabinoid-based products.
• The company believes it is positioned to develop multiple pharmaceutical Product Candidates in diseases which may benefit from medicines based on rare cannabinoid compounds.
• The company intends to deliver its rare cannabinoid pharmaceutical Product Candidates through various topical formulations.
• The company expects its expenses will remain steady as it seeks partnerships, advances research, and scales up manufacturing processes.

Industry Context

The company operates in the emerging cannabinoid-based pharmaceutical and health and wellness sectors. The increase in revenue from the BayMedica segment reflects a growing demand for rare cannabinoids in the health and wellness industry. However, the company's financial challenges highlight the risks and uncertainties associated with drug development and commercialization in this sector.

Comparison to Industry Standards

• Compared to other clinical-stage pharmaceutical companies, InMed's revenue is relatively low, reflecting its early stage of development and reliance on the BayMedica segment for revenue.
• The company's net loss is consistent with other companies in the pharmaceutical sector that are still in the research and development phase.
• The company's going concern warning is not uncommon for early-stage biotech companies that are heavily reliant on external funding.
• The company's reliance on private placements for funding is a common practice for companies in this sector, but it also highlights the need for a more sustainable revenue model.
• The company's focus on topical delivery of cannabinoids is a differentiating factor compared to companies that focus on oral or inhaled delivery methods.

Legal Proceedings

• BayMedica is involved in a dispute with a licensor regarding a patent license agreement.

Related Party Transactions

• Norton Rose Fulbright Canada LLP, where a director is a partner, provided legal services to the company.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity financings and potential loss of investment due to the company's going concern status.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company fails to secure additional funding.
• Customers of BayMedica may be affected by potential supply chain disruptions if the company's financial situation worsens.
• Suppliers and creditors face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will continue to seek partnerships to advance the INM-755 program.
• The company will continue to advance research into the role of cannabinoids in treating ocular diseases.
• The company will continue to advance research in the INM-901 and INM-089 programs.
• The company will investigate its Product Candidates for additional uses beyond their initial target indications.
• The company will pursue the discovery of drug targets based on proprietary cannabinoid analogs.
• The company will seek regulatory approvals for any Product Candidates that successfully complete clinical trials.
• The company will scale-up its manufacturing processes and capabilities.
• The company will continue to support its commercial operations and revenue-generating Products at BayMedica.
• The company will execute on business development activities.
• The company will maintain, expand, enforce, defend and protect its intellectual property.
• The company will continue to further advance the research and development of various manufacturing technologies.
• The company will build internal infrastructure, including personnel, to meet its milestones.
• The company will add operational, financial and management information systems and personnel.

Key Dates

Keywords

cannabinoids, pharmaceuticals, BayMedica, clinical stage, rare cannabinoids, IntegraSyn, manufacturing, research and development, going concern, private placement, financial results